Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pre-operative Docetaxel for Progressive Localized Castration Resistant Prostate Cancer
NCT00811031Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of docetaxel in prostate cancer (PCa), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Increase in phosphorylation of platelet-derived growth factor receptor at day 42. Status: withdrawn.
02
Drugs
docetaxel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00811031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00811031.